DaVita (DVA) to Release Earnings on Tuesday

DaVita (NYSE:DVA) is scheduled to be announcing its earnings results after the market closes on Tuesday, October 29th. Analysts expect the company to announce earnings of $2.76 per share for the quarter. DaVita has set its FY24 guidance at $9.25-10.05 EPS and its FY 2024 guidance at 9.250-10.050 EPS.Investors interested in participating in the company’s conference call can do so using this link.

DaVita (NYSE:DVA) last posted its quarterly earnings data on Tuesday, August 6th. The company reported $2.59 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.47 by $0.12. DaVita had a return on equity of 77.00% and a net margin of 6.86%. The company had revenue of $3.19 billion for the quarter, compared to the consensus estimate of $3.15 billion. During the same period in the previous year, the business earned $2.08 EPS. DaVita’s revenue for the quarter was up 6.2% compared to the same quarter last year. On average, analysts expect DaVita to post $10 EPS for the current fiscal year and $11 EPS for the next fiscal year.

DaVita Price Performance

DVA stock opened at $156.99 on Monday. The company has a quick ratio of 1.12, a current ratio of 1.16 and a debt-to-equity ratio of 9.94. DaVita has a 52-week low of $75.47 and a 52-week high of $168.50. The stock’s 50 day moving average is $158.09 and its two-hundred day moving average is $145.67. The company has a market capitalization of $13.77 billion, a PE ratio of 17.84, a P/E/G ratio of 0.93 and a beta of 0.87.

Insider Transactions at DaVita

In other news, CFO Joel Ackerman sold 64,029 shares of the business’s stock in a transaction on Tuesday, August 27th. The stock was sold at an average price of $155.06, for a total transaction of $9,928,336.74. Following the sale, the chief financial officer now directly owns 111,481 shares of the company’s stock, valued at $17,286,243.86. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. In other news, CFO Joel Ackerman sold 64,029 shares of the business’s stock in a transaction on Tuesday, August 27th. The stock was sold at an average price of $155.06, for a total transaction of $9,928,336.74. Following the sale, the chief financial officer now directly owns 111,481 shares of the company’s stock, valued at $17,286,243.86. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CEO Javier Rodriguez sold 50,000 shares of the company’s stock in a transaction on Monday, September 16th. The shares were sold at an average price of $165.05, for a total value of $8,252,500.00. Following the transaction, the chief executive officer now directly owns 837,835 shares in the company, valued at $138,284,666.75. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 173,482 shares of company stock valued at $27,387,069. Corporate insiders own 2.00% of the company’s stock.

Wall Street Analysts Forecast Growth

DVA has been the topic of several analyst reports. UBS Group lifted their price objective on DaVita from $169.00 to $175.00 and gave the stock a “buy” rating in a report on Thursday, August 8th. Bank of America boosted their price objective on DaVita from $139.00 to $145.00 and gave the company an “underperform” rating in a research report on Wednesday, August 7th. Truist Financial boosted their price objective on DaVita from $165.00 to $175.00 and gave the company a “hold” rating in a research report on Monday, October 7th. Finally, TD Cowen boosted their price target on DaVita from $139.00 to $150.00 and gave the stock a “hold” rating in a research report on Wednesday, July 24th. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating and two have assigned a buy rating to the company’s stock. According to MarketBeat, DaVita presently has a consensus rating of “Hold” and a consensus target price of $159.00.

About DaVita

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.